In one trial, 635 patients with previously resected colorectal cancer received daily aspirin (325 mg) or placebo. During an average follow-up of 31 months (during which most patients underwent 1 ...

Please provide your email address to receive an email when new articles are posted on . Low-dose aspirin significantly reduced risk for colorectal cancer recurrence among patients with mutations ...

Aspirin reduced colorectal cancer recurrence risk by 50% in patients with PIK3CA mutations over three years. Mutations in the PI3K pathway predict aspirin response, broadening its use to more patients ...

WEDNESDAY, Jan. 29, 2025 (HealthDay News) -- Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new study says. Taking 160 milligrams of ...

Seohyuk Lee et al, Adjuvant aspirin therapy and colorectal cancer survival, The Lancet Gastroenterology & Hepatology (2025). DOI: 10.1016/S2468-1253(24)00393-5 Journal information: The Lancet ...

Opens in a new tab or window Treating patients with aspirin after completion of standard adjuvant therapy for colorectal cancer failed to significantly improve disease-free survival (DFS ...

Opens in a new tab or window SAN FRANCISCO -- In an era dominated by pricey, high-tech drugs, the humble aspirin had a practice-changing impact on colorectal cancer (CRC) recurrence, according to ...

Daily low-dose aspirin can help prevent cancers from returning in about a third of colon cancer patients, a new study says. Taking 160 milligrams of aspirin a day cuts the risk of cancer ...

Cancer risk was cut by half in patients with a mutation that makes them more susceptible Overall, aspirin patients were 55% less likely to have cancer recur than those taking a placebo WEDNESDAY ...